For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, with price reductions or rebates up to 50%, it could meet the benchmark for value in healthcare. An article in the Canadian Journal of Cardiology, published by Elsevier, details a statistical model analyzing the cost-effectiveness of semaglutide. It provides evidence for policymakers considering the benefits of funding semaglutide for individuals without diabetes and the budgetary impact for long-term health gains.

Facing high employee turnover and an aging population, nursing homes have increasingly turned to robots to complete a variety of care tasks, but few researchers have explored how these technologies impact workers and the quality of care. A new study from a University of Notre Dame expert on the future of work finds that robot use is associated with increased employment and employee retention, improved productivity and a higher quality of care.

Jeremy Forsberg, associate vice president of research and innovation at The University of Texas at Arlington, has been named to chair a leadership committee within the Council on Governmental Relations (COGR), the national authority on federal policies and regulations affecting U.S. research institutions.